Nordic Nanovector Appoints Eduardo Bravo as Chief Executive Officer
Oslo, Norway, 25 June 2018 Nordic Nanovector ASA (OSE: NANO) announces that Eduardo Bravo has been appointed as its Chief Executive Officer. Mr Bravo brings more than 25 years’ experience in the biopharmaceutical industry and a strong track record in leading and growing international biotech and pharmaceutical organisations. Since 2011, as CEO of TiGenix, a dual-listed (Euronext Brussels and NASDAQ) biopharmaceutical company developing novel stem cell therapies, he successfully developed the company through several financing rounds, led its IPO on NASDAQ, and secured European